DEVELOPMENT HISTORY

Lanke Biotechnology officially embarked on its journey in 2025. From the very inception, we have established the core development path of "Basic Research-Driven Clinical Translation".

In our first year of operation, our team completed a systematic strategic layout of key underlying technologies including gene editing and non-viral delivery, and successfully launched our self-developed full-chain technology platform. Meanwhile, we initiated the advancement of multiple Ex vivo CAR pipelines and forged cooperative relationships with a number of tertiary care hospitals.

Initial Stage

Rooted in basic medical care and basic research, we built our core team and scientific research platforms, consolidating the solid foundation for the development of our core disciplines.

Growth Stage

We focus on in-depth cultivation of our core professional directions, optimize the development of our talent echelons, and continuously expand our landscape in clinical diagnosis and treatment, basic scientific research and academic exchange.